Is STVN a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Stevanato Group S.p.A. (STVN) rests on The high-value solutions mix shift: Ready-to-use sterilized containers and integrated delivery systems reached ~46% of third-quarter 2026 revenue at ~EUR 149.4 million, and ~51% within the Biopharmaceutical and Diagnostic Solutions segment. The bear case rests on customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month. Analysts covering it publish targets from $16.00 to $25.00 against a $15.65 share price on November 20, 2026, so even the professionals disagree by 46% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

STVN key stats

At $15.65 on November 20, 2026, Stevanato Group S.p.A. (STVN) has a market cap of $4.3B, a P/E of 26.5 on trailing earnings (21.6 on forward earnings) and a dividend yield of 0.38%.

Market cap
$4.3B
P/E (trailing)
26.5
P/E (forward)
21.6
EPS (trailing 12 months)
$0.59
Price to book
2.4
Dividend yield
0.38%
Beta
0.80

Market cap, P/E and yield are measured at the $15.65 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Stevanato Group S.p.A. (STVN)?

The last two weeks for Stevanato Group S.p.A., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • STVN closed at $15.65 on November 20, 2026, down 0.9% over the past five trading days (from $15.80).
  • On November 12, 2026, Stevanato Group S.p.A. filed a current report (6-K) with the SEC. Read the 6-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Stevanato Group has been making pharmaceutical glass in Piombino Dese, near Padua in northern Italy, since 1949, and sells its containers under the Ompi brand. The business runs in two segments. Biopharmaceutical and Diagnostic Solutions covers vials, syringes, cartridges, EZ-fill ready-to-use containers and the Alina pen injector platform, and produced ~EUR 294 million of the ~EUR 326.1 million total in the third quarter of 2026. Engineering builds the assembly, visual inspection and glass converting machinery that drug makers and other packaging firms use on their own lines, and contributed the remaining ~EUR 32 million. The company listed ordinary shares on the New York Stock Exchange in July 2021, but it remains an Italian issuer that reports in euros and files as a foreign private issuer, and the founding family retains roughly four fifths of the shares through Stevanato Holding S.r.l., with Italian loyalty-share rules adding extra votes on top of that. The investment picture turns on mix. Ordinary bulk glass is a commodity with thin margins and a customer base that periodically works down inventory, which is exactly what caused the 2024 destocking shock. What Stevanato calls high-value solutions, meaning sterilized ready-to-use containers and integrated delivery devices, carries far better economics and reached ~46% of third-quarter revenue at ~EUR 149.4 million, though it grew only ~1% year over year as GLP-1 volumes fell, while other containment and delivery solutions grew ~22% and the total grew ~8%. Third-quarter adjusted EBITDA rose ~14% to ~EUR 88.8 million, a ~27.2% margin and up ~150 basis points, and adjusted EPS was ~EUR 0.16. Against that, the company is spending heavily to build the capacity the shift requires, at Fishers in Indiana and Latina in Italy, with full-year capital expenditure guided to ~EUR 230 million to ~EUR 240 million gross. Third-quarter free cash flow turned positive at ~EUR 21.7 million and net debt eased to ~EUR 353.7 million, but buyers of the shares are still funding a multi-year build-out before the returns on it arrive. Stevanato also completed the sale of Balda C. Brewer, a California subsidiary expected to contribute ~EUR 30 million of 2026 revenue, on June 30, and reaffirmed its trimmed full-year guidance with the November results. The stock reaction came from 2027: management said one customer's lower GLP-1 volumes, tied to Nexa syringes, would moderate next year's growth to low single digits, called it a temporary headwind it expects to largely backfill, and reported GLP-1 at ~17% to ~18% of revenue, down from ~22% to ~23% in the second quarter. William Blair downgraded the shares, UBS cut its target to $16 from $23, and plaintiff firms announced investigations into the company's GLP-1 disclosure. As of November 20, 2026 the stock traded at ~$15.70, against a 52-week range of ~$12.05 to ~$24.01.

The bull case: what would have to be true for $25.00

The most optimistic published target on STVN is $25.00, +59.7% from the $15.65 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. The high-value solutions mix shift

Ready-to-use sterilized containers and integrated delivery systems reached ~46% of third-quarter 2026 revenue at ~EUR 149.4 million, and ~51% within the Biopharmaceutical and Diagnostic Solutions segment. Growth slowed sharply to ~1% year over year in the quarter, from ~16% in the second quarter, because lower GLP-1 volumes sit inside this category. The margin effect of the mix is still visible in the ~27.2% adjusted EBITDA margin, up ~150 basis points, but the pace of the shift now depends on how quickly non-GLP-1 programs fill the gap.

2. Injectable biologics volumes, GLP-1 included

GLP-1 therapies fell to roughly ~17% to ~18% of total revenue in the third quarter, down from ~22% to ~23% on the second-quarter call, while non-GLP-1 biologics revenue rose more than ~30% in the quarter and ~13% year to date. Management continues to frame the wider injectable pipeline as the larger opportunity, having cited more than ~9,000 injectable assets in development with around ~60% of them biologics. Each of those needs a container that will not react with the molecule and, increasingly, a device the patient can use at home, and approval across several European markets for a liraglutide therapy on the Alina pen platform moved Stevanato from selling a component to selling an assembled system. The open question is 2027: one customer's lower GLP-1 volumes tied to Nexa syringes will hold growth to low single digits next year, which management calls temporary, and the 2026 arrival of oral GLP-1 pills adds a second question about how much injectable volume the obesity class will need. Peers are seeing the same pressure, with RBC and UBS both turning cautious on Schott Pharma in November over GLP-1 syringe demand.

3. New capacity in the United States and Italy

The Fishers, Indiana site completed initial performance qualification on its first EZ-fill vial line and expects commercial production for its first device program later in 2026, with full ramp-up guided to the end of 2028. Latina in Italy is running alongside it. Full-year 2026 capital expenditure is guided to ~EUR 230 million to ~EUR 240 million gross, or ~EUR 215 million to ~EUR 225 million net of customer contributions. Pharmaceutical customers under pressure to localize supply chains give a European supplier with US plants an argument it did not have five years ago, though the payoff sits several years out, and slower 2027 volumes stretch the time before the new lines are full.

4. A possible turn in Engineering

Engineering revenue fell ~12% year over year to ~EUR 32 million in the third quarter, after a ~2% decline to ~EUR 35.8 million in the second. Management said the same customer behind the lower GLP-1 forecast is also delaying engineering orders, cut the segment's full-year outlook modestly to ~EUR 124 million to ~EUR 134 million, and said it is still evaluating the segment's strategic path. That makes Engineering a swing factor and possibly a candidate for a structural change, not a reliable driver. The June 2026 sale of the Balda C. Brewer subsidiary already trimmed revenue by ~EUR 30 million this year in exchange for a cleaner margin profile.

The bear case: what would have to be true for $16.00

The most pessimistic published target is $16.00, +2.2% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Stevanato Group S.p.A. is worth if the risks below bite instead of the drivers above.

Customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month. Plaintiff firms opened investigations after both episodes, the latest focused on the company's GLP-1 disclosure; those are investigations, not filed litigation, as far as the public record shows. Capital intensity remains the near-term drag, with full-year 2026 capital expenditure guided to ~EUR 230 million to ~EUR 240 million gross, trailing free cash flow of ~negative $65 million on Yahoo's basis and net debt of ~EUR 353.7 million at the end of September. GLP-1 exposure now reads as ~17% to ~18% of revenue, still a single point of failure if pricing, supply or dosing formats change, and the 2026 launch of oral GLP-1 pills turned the dosing-format risk from hypothetical to live. Governance leaves outside holders with limited influence, because family control through Stevanato Holding S.r.l. plus enhanced voting rights means minority shareholders cannot force a change of direction. Finally, the reporting currency is the euro while the quote is in dollars, so a US holder absorbs the exchange rate on top of the operating result, and at roughly ~27 times trailing and ~22 times forward earnings as of November 2026 the price still assumes the mix shift and the new plants deliver once the 2027 slowdown passes.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding STVN already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on STVN

12 analysts cover STVN, with an average target of $19.46 (+24.3% against $15.65) and a split of 9 buy, 4 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the STVN forecast and price target page.

How is STVN valued?

Market cap, P/E and dividend yield at today's price are in the STVN key stats above. The business figures below come from Stevanato Group S.p.A.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~EUR 1.25 billion, Q3 2026 up ~8% year over year
  • Q3 2026 revenue: ~EUR 326.1 million, adjusted diluted EPS ~EUR 0.16 (Yahoo basis 0.18 vs 0.18 est.)
  • Margins (TTM): gross ~29%, operating ~18%, net ~11%
  • Net income (TTM): ~EUR 140 million
  • FY2026 company guidance (reaffirmed): revenue ~EUR 1.26 to ~EUR 1.28 billion, adjusted diluted EPS ~EUR 0.60 to ~EUR 0.62

As of November 2026: Every operating figure above is reported in euros because Stevanato is an Italian issuer, while the share price and market capitalization are quoted in US dollars on the NYSE, so the two sets of numbers move on different currencies and should not be compared directly. The trailing multiple has come down from ~33 times in October to ~27 times as of November 20, 2026, as the shares fell ~19% in a month on the 2027 GLP-1 warning, and consensus now looks for 2027 EPS of ~0.72 on ~EUR 1.3 billion of revenue, about ~6% growth. The analyst mean target was ~$19.46 across 12 analysts, with a Buy consensus despite the William Blair downgrade.

How do you decide if STVN is a buy?

Whether STVN is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold STVN indirectly through an index or sector ETF before adding more.

What would change your mind on STVN

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: The high-value solutions mix shift stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the STVN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about STVN against your real portfolio and see your actual exposure before deciding.

Your questions about Stevanato Group S.p.A.

Ask Walnut's AI anything about STVN and see how it fits what you own.

FAQ

Is STVN a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on The high-value solutions mix shift, with revenue (ttm) at ~EUR 1.25 billion, Q3 2026 up ~8% year over year. The bear case rests on customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month. Analysts covering it are spread from $16.00 to $25.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell STVN?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $16.00, +2.2% from the $15.65 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for STVN?

+

The high-value solutions mix shift. Ready-to-use sterilized containers and integrated delivery systems reached ~46% of third-quarter 2026 revenue at ~EUR 149.4 million, and ~51% within the Biopharmaceutical and Diagnostic Solutions segment. The most optimistic analyst target on STVN is $25.00, +59.7% from the $15.65 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for STVN?

+

Customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month. Plaintiff firms opened investigations after both episodes, the latest focused on the company's GLP-1 disclosure; those are investigations, not filed litigation, as far as the public record shows. Capital intensity remains the near-term drag, with full-year 2026 capital expenditure guided to ~EUR 230 million to ~EUR 240 million gross, trailing free cash flow of ~negative $65 million on Yahoo's basis and net debt of ~EUR 353.7 million at the end of September. GLP-1 exposure now reads as ~17% to ~18% of revenue, still a single point of failure if pricing, supply or dosing formats change, and the 2026 launch of oral GLP-1 pills turned the dosing-format risk from hypothetical to live. Governance leaves outside holders with limited influence, because family control through Stevanato Holding S.r.l. plus enhanced voting rights means minority shareholders cannot force a change of direction. Finally, the reporting currency is the euro while the quote is in dollars, so a US holder absorbs the exchange rate on top of the operating result, and at roughly ~27 times trailing and ~22 times forward earnings as of November 2026 the price still assumes the mix shift and the new plants deliver once the 2027 slowdown passes. The most pessimistic published target is $16.00, +2.2% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does Stevanato Group S.p.A. do?

+

Stevanato Group is an Italian family-controlled maker of pharmaceutical glass vials, syringes and cartridges, plus pen injectors and packaging machinery.

What would have to change for STVN to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The high-value solutions mix shift) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Stevanato Group actually make?

+

Containers and devices for injectable medicines. That covers glass vials, prefillable syringes and cartridges under the Ompi brand, sterilized ready-to-use EZ-fill formats, and the Alina pen injector platform. A separate Engineering segment builds the assembly, filling and visual inspection machinery that drug makers run on their own production lines.

Is STVN a real US listing or an over-the-counter receipt?

+

Ordinary shares of Stevanato Group S.p.A. trade directly on the New York Stock Exchange under STVN, following the July 2021 initial public offering. No sponsored or unsponsored depositary receipt sits in between, and the company files with the SEC as a foreign private issuer, using Form 20-F annually and Form 6-K for quarterly results.

Why are Stevanato's results reported in euros?

+

The company is headquartered in Piombino Dese, Italy, and keeps its books in euros, so revenue, margins and earnings per share all arrive in EUR even though the shares are quoted in USD. Third-quarter 2026 revenue of ~EUR 326.1 million and adjusted diluted EPS of ~EUR 0.16 are euro figures. Putting a dollar sign on them overstates or understates the result depending on the exchange rate that day.

Walnut is informational, not investment advice, and gives no verdict on STVN. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks